This Monopoly Stock Powers Every AI Chip on the Planet, and It's Down Over 14% This Month

Net bookings more than doubled quarter‑over‑quarter to 13,158 (Q4 2025) from 5,399 (Q3 2025) and full‑year orders rose to 28,035, including an $8.0B EUV order from SK Hynix. 2025 revenue was €32.6B (+15% YoY) with EPS +28%, net profit margin 29% and debt/equity 0.22; shares roughly doubled over the past year then fell 14% recently, while average analyst targets imply ~24% upside and top estimates imply ~60% to ~$2,000. The article argues ASML retains a de facto monopoly on EUV lithography, its Chinese rival won’t be production‑ready until ~2028–2030, and recommends buying the dip given strong demand and financials.

Analysis

ASML’s monopoly creates concentrated upstream leverage: fabs that need EUV have locked multi-year capital plans, which pushes component suppliers (high-power lasers, precision optics, metrology) into multi-year lead times and price rigidity. That concentration means ASML’s revenue is less cyclically sensitive to a single quarter slowdown and more sensitive to multi-year execution risk across its supply chain; expect supplier lead times to extend into the 18–36 month band and margin upside to be magnified as fixed-cost absorption improves.

The main medium/long-term threat is not a single competitor launch but three interacting risks — acceleration of indigenous Chinese EUV capability (plausible 2028–2032), shifts in export controls that either restrict or redirect demand, and component bottlenecks or yield problems at customers that delay machine acceptance. In the near term (days–months) geopolitical headlines will produce volatile 10–20% swings; over 12–36 months the real inflection will be visible in deliveries converted from bookings and in whether Chinese units materially close the performance gap.

The cleanest way to express conviction is convex option exposure or a hedged equity build: buy long-dated calls or accumulate shares on pullbacks while capping downside with puts or collars. A useful stress test is monitoring NVDA’s wafer demand and a supplier lead-time index — if NVDA’s demand growth stalls, trim exposure within 30–90 days. Finally, the market may be underpricing concentration risk: ASML enjoys pricing power today, but a credible Chinese alternative or a policy shift could compress valuation quickly, so size and hedges should reflect a concentrated-single-supplier tail risk.

Key Decisions for Investors

• Core bullish, defined-cost: Buy ASML via an 18–24 month call spread (long LEAP call, sell nearer-term call) sized 2–4% NAV to capture upside while capping premium; target 50–80% gross upside, max loss = premium paid, breakeven if delivery cadence improves within 12 months.
• Hedged equity accumulation: Build a 5–8% ASML position on a two-step scale into 6–12% pullbacks; protect with 6–9 month puts (20% OTM) or construct a collar to limit downside to ~20% while keeping 50–60% upside to analysts’ high cases over 12–24 months.
• Relative idea (event-driven, 6–18 months): Pair trade long ASML / short INTC (equal notional) to isolate ASML’s EUV pricing power vs Intel’s manufacturing execution risk; expect spread widening ~30–50% if ASML converts backlog and Intel misses node/tapeout targets. Stop-loss: 12% on either leg.
• Signal/watch: Use NVDA quarterly shipment/guide and a supplier lead-time index as triggers — if NVDA demand growth decelerates materially on guidance, trim ASML exposure by 25–50% within 30–90 days; conversely, add if NVDA accelerates and ASML delivery confirmations rise.